Standigm-Qurom Collaborate on Rare Disease Drug Development

Standigm and Qurom Biosciences announced on the 26th that they signed a Memorandum of Understanding (MOU) for the development of rare disease treatments on the 25th at Standigm's headquarters conference room in Gangnam-gu, Seoul. The signing ceremony was attended by Standigm CEO Choo Yeon-seong and Qurom CEO Yoon Ju-seok, among others.

Chuyeonseong, CEO of Standum (left), and Yoon Juseok, CEO of Qurom Biosciences, are posing for a commemorative photo. Photo by Standum

Through this MOU, the two companies will combine Standigm's artificial intelligence (AI) drug discovery platform with Qurom's research and development capabilities for rare disease treatments to jointly conduct the discovery of new treatments in the field of rare diseases such as mitochondrial dysfunction, as well as preclinical, clinical development, and business development.

Qurom CEO Yoon Ju-seok stated, "By combining Standigm's AI platform technology with Qurom's core technology related to NAD+ promotion and mitochondrial activation, we will actively pursue the development of treatments for rare diseases such as mitochondrial dysfunction. This will serve as a foothold for Qurom to become the world's number one company in the field of rare intractable disease treatments." Standigm CEO Choo Yeon-seong also said, "We are very pleased to collaborate with Qurom, which has excellent research capabilities in rare disease treatment development. Through the cooperation of both companies, Standigm's AI platform technology will be further strengthened, and based on this, we expect rapid commercialization success for both companies."

This content was produced with the assistance of AI translation services.